Etoricoxib (90 mg once daily) is more effective than placebo and similar in efficacy to naproxen (500 mg twice daily) over a 12-week period, for treating patients with rheumatoid arthritis over 12 weeks.
Moreover, patients generally tolerate this dosage well, suggests a multinational randomised, controlled clinical trial for the Etoricoxib Rheumatoid Arthritis Study Group.
Etoricoxib is a highly selective COX-2 inhibitor. Eduardo Collantes and colleagues from the Hospital Reina Sofia, Cordoba, Spain did this 12-week study with others from centres in the United States, Hong Kong, Colombia and Canada, conducted at 67 sites in 28 countries.
Participants were all chronic users of nonsteroidal anti-inflammatory drugs (NSAIDs) who showed a clinical worsening of arthritis on pre-study withdrawal of these drugs.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!